Background {#Sec1}
==========

Mental health disorders, including anxiety and post-traumatic stress disorder (PTSD) are among the leading contributors to global disability adjusted life years, comprising five of the top twenty contributing disorders \[[@CR1]\]. The World Health Organization International Classification of Disease (ICD-11) defines anxiety as a disorder in which there is an extreme and excessive focus on an "anticipated threat" and defines PTSD as a disorder that results from exposure to one or more "horrific events", both of whose symptoms include apprehension, motor tension and autonomic overactivity \[[@CR2]\]. In 2017, it was estimated that over 264 million people experienced an anxiety disorder, with the global prevalence for both anxiety disorders and PTSD ranging from 2.5 to 7% by country \[[@CR2]--[@CR4]\]. Both anxiety and PTSD are widespread common mental disorders (CMDs) that have been shown to cause significant negative health outcomes within various populations and contribute to a large portion of the global disease burden \[[@CR5], [@CR6]\]. There are noteworthy discrepancies in quality of life between people diagnosed with anxiety and/or PTSD and those who are not diagnosed with either, such as increased years lived with disability and decreased life expectancy \[[@CR7]--[@CR9]\]. Additionally, there is evidence suggesting that the presence of an anxiety disorder or PTSD increases the likelihood of comorbidity with other severe health conditions, such as major depressive disorder and substance use disorder \[[@CR10], [@CR11]\].

Anxiety and PTSD in low to middle income countries (LMICs) are highly prevalent and require further study given that access to care is hindered by availability and stigma \[[@CR12]--[@CR14]\]. Prevalence of these disorders is higher within LMICs; roughly 83% of people with mental illnesses globally are living within LMICs \[[@CR15]\]. In many LMICs, there is no robust mental healthcare system in place and the number of mental health professionals is sparse \[[@CR16]\]. Assessment and diagnosis of psychiatric illnesses thus often falls to primary care and general practitioners who have little training in mental health \[[@CR16]\]. Use of brief screening tools have been proposed as a way to improve identification and management of mental health problems, and may be useful in LMICs, especially among populations with elevated risk (e.g., pregnant women, refugees/displaced persons, and youth) within LMIC communities \[[@CR17]--[@CR19]\].

Despite multiple screening instruments for CMDs, there are significantly fewer screening instruments for anxiety and PTSD that have been validated in LMIC populations. Screening instruments that have been validated exclusively in high-income countries may not perform equivalently in LMIC populations, as anxiety and PTSD often present differently in different cultural contexts. For example, in sub-Saharan Africa, anxiety and PTSD are described through somatic symptoms as well as spiritual descriptions \[[@CR20]\]. Furthermore, differences in clinical presentation may render screening tools less accurate in LMICs. Thus, optimum cut-off scores validated in high income populations may not apply in LMIC populations. For instance, in a sample of 75 participants from Tajikistan \[[@CR21]\], the optimal cut-off of 1.88 for the Harvard Trauma Questionnaire (HTQ), a measure of PTSD, was substantially lower than the standard cut-off score of 2.5 that has been recommended in previous studies in high-income countries \[[@CR22]\]. Failure to apply suitable cut-off scores may lead to an imbalance of positive and negative screening results. If chosen cutoffs are too high, actual cases of anxiety and PTSD may not reach the threshold for further assessment and diagnosis; thus, cases will be missed. Conversely, if chosen cutoffs are too low, there may a very large number of positive screens requiring substantial resources for further assessment, and healthcare systems may not be able to manage the load.

Although there has been an increasing interest in studying mental health within LMICs, there are still large gaps related to screening tools to assess mental health disorders, especially anxiety and PTSD. The most recent systematic review investigating screening tools for CMDs in LMICs was published in 2016 \[[@CR23]\]. Of the 273 validations included, 236 were validated tools for CMDs or depressive disorders while only 24 and 13 validated tools for anxiety and PTSD, respectively. Therefore, the objective of this study was to conduct a systematic review of screening tools for anxiety and PTSD within LMIC populations.

Methods {#Sec2}
=======

Aim: To validate screening tools for anxiety disorders and PTSD in LMICs.

We published a study protocol in advance in the PROSPERO registry (CRD42019121794).

Search strategy and study selection {#Sec3}
-----------------------------------

We systematically searched four databases (MEDLINE, EMBASE, Global Health and PsychINFO) from inception to April 22, 2020 (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Search strategy

Inclusion criteria {#Sec4}
------------------

Our eligibility criteria required that studies: (1) screen specifically for anxiety (generalized anxiety disorder or anxiety disorders not otherwise specified) and/or PTSD; (2) provide estimates of sensitivity and specificity for a given cut-off value for one of the included disorders; (3) were conducted in a LMIC (based on the World Bank Classification) \[[@CR24]\]; and (4) compare screening results to a validated reference standard. Reference standards included unstructured clinical diagnostic interviews as well as structured clinical interviews including the Mini International Neuropsychiatric Interview (MINI and MINI-KID) \[[@CR25]\], Structured Clinical Interview for DSM (SCID, SCID-1 and NetSCID) \[[@CR26], [@CR27]\], Composite International Diagnostic Interview (CIDI and CIDI-PHCV) \[[@CR28]\], Clinical Interview Schedule-Revised (CIS-R) \[[@CR29]\], Psychiatric Assessment Schedule (PAS) \[[@CR30]\], Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS and K-SADS-PL) \[[@CR31]\] and Clinician-Administered PTSD Scale (CAPS and CAPS-5) \[[@CR32], [@CR33]\]. LMIC populations residing in a LMIC at the time of study were included. No search restrictions were put on age, gender or comorbidities.

Exclusion criteria {#Sec5}
------------------

We excluded papers that did not report sensitivity, specificity and cut-off value; that were not published in English; and that involved populations originally from an LMIC residing outside a LMIC at the time of the study. Persons from an LMIC residing in another LMIC at the time of the study were included (e.g., refugee populations and displaced persons).

Literature review {#Sec6}
-----------------

Abstracts returned from the search were reviewed separately by two independent reviewers for inclusion, with any discrepancies resolved by discussion and use of a third senior reviewer as needed. For abstracts meeting inclusion criteria, full-text articles were retrieved and reviewed by two separate reviewers for final inclusion, with discrepancies resolved by discussion and use of a third senior reviewer as needed. We also searched the reference lists of relevant systematic reviews for additional articles to add to our full-text review.

Quality appraisal {#Sec7}
-----------------

To assess study quality, we used a modified version of Greenhalgh's ten item checklist previously used in a study by Ali et al. \[[@CR23]\] Elements of the quality checklist are provided in Fig. [2](#Fig2){ref-type="fig"}. Credit was given for translation if a previously validated translated version of the tool or reference standard was used, or if the tool was administered in English. Studies of 'very good' quality fulfilled all the quality criteria. Studies deemed 'good' quality fulfilled criteria 1 through 3 in addition to at least one other criterion from 4 to 5. 'Fair' quality studies did not avoid work-up bias and 'acceptable' quality studies did not perform receiver operating characteristic curve (ROC) analysis to determine a normal range from the results. 'Unblinded' studies include studies that reported the interviewers were not blinded to the screening results; if the study did not specify whether the screening tool administrators and interviewers were blinded to each other's results, we considered it unblinded but clarified this designation was unconfirmed. Fig. 2A modified Greenhalgh's ten item checklist, adapted from Ali et al. \[[@CR23]\]

Data abstraction and analysis {#Sec8}
-----------------------------

Numerical data was abstracted by one reviewer and checked by a separate reviewer to ensure quality extraction. Data abstraction sheets included extraction of the screening tool and disorder, number of participants, DSM version, screening tool administrator, language, region, population study characteristics and age, country, gold standard, area under the curve (AUC), cut-off score, sensitivity and specificity. If multiple screening tools and/or cut-offs were used, data was extracted for each cutoff, for each tool, separately. If values were split by population, the value most representative of the total was chosen (e.g., community values for data split by hospital inpatient unit). If multiple cut-offs were given without AUC, we extracted the set of values for the cutoff that maximized Youden's J \[[@CR34]\]. Results were presented separately by disorder, screening tool and cut-off value. As anxiety and depression were combined in many screening tools, a third category of mixed anxiety and depression was included.

For validations of screening tools for the same disorder that used identical cut-off values, bivariate random-effects meta-analytic models were fitted to provide estimates of pooled sensitivity and specificity for the cut-off value.

Results {#Sec9}
=======

Study selection {#Sec10}
---------------

Of 6322 unique citations identified from the database search, 6188 were excluded after title and abstract review and five additional papers from the reference lists of relevant systematic reviews were added. Of 140 included for full-text review, 81 were excluded, leaving 59 eligible articles inclusive of 77 screening tools (see Fig. [3](#Fig3){ref-type="fig"}). The most common reasons for exclusion were not screening for the disorder of interest, not comparing to a gold standard, and failing to provide either sensitivity/specificity data or a threshold for screening. Fig. 3Flow chart of study selection

Quality appraisal {#Sec11}
-----------------

Two studies met all the criteria of the modified Greenhalgh's ten item checklist and deemed 'very good' quality while 20 studies were deemed to be 'good' quality, due to lack of reporting the confidence intervals for sensitivity, specificity or AUC. Two studies were 'fair' quality for not avoiding work-up bias and five were deemed 'acceptable' for failing to perform ROC analysis. A total of 29 studies were labelled 'unblinded' for failing to specify if they blinded the researchers or for explicitly stating they were not blinded (see Table [1](#Tab1){ref-type="table"}). Table 1Quality rating statisticsQuality RatingNumber of StudiesVery good2Good20Fair2Acceptable5Unblinded29Total58

Description of included studies {#Sec12}
-------------------------------

The final 59 studies selected included a total of 77 screening tools. There were 46 validations of screening tools for anxiety disorders, 19 for PTSD and 12 for anxiety and depression (see Table [2](#Tab2){ref-type="table"}). Table 2Screening tool validation by disorder categoryDisorder CategorySpecific disordersTotalAnxiety DisordersGeneralized Anxiety Disorder46Panic DisorderSocial Anxiety DisorderAnxiety Disorder NOSPTSDPTSD19Anxiety and DepressionGeneralized Anxiety Disorder12Major Depressive Disorder**Total77**

A minority of studies accounted for children and adolescent validations (10) despite a relatively young demographic present in LMICs \[[@CR35]\]. The majority of validations studied adults (36), with a select few including adolescents and adults (6) (see Table [3](#Tab3){ref-type="table"}). Particularly well-represented groups included the general population and clinical outpatients (13), perinatal populations (6), psychiatric patients (7) and those with another psychiatric comorbidity (7) (see Table [3](#Tab3){ref-type="table"}). Of the 19 validations for PTSD, only four studied children and adolescents. Table 3Distribution by age a population characteristicPopulation DescriptorsNumber of Studies**Adults (36)**Outpatients**5**General Population**7**HIV**4**Psychiatric patients**7**Conflict area/refugee**4**Other or unspecified**9Perinatal (6)**HIV**1**Other**5Adolescents and Adults (6)**Survivors of natural disaster**2**Other**4Children and/or Adolescents (10)**Psychiatric Patient**2**Survivor of natural disaster**2**Other**6**

The majority of screening tool validations were in Asia (35) followed by Africa (20), the Americas (5) and Europe (1) (see Table [4](#Tab4){ref-type="table"}). The best represented regions include South and West Asia, as well as South and East Africa, with a noticeable gap in Middle and Northern Africa. There were no studies from the Oceanic region. Table 4Number of Studies by Region and CountryContinentRegionCountry (Number of Studies)LMICs with no studiesAfrica (20)NorthNone6 (Sudan, Algeria, Egypt, Libya, Morocco, Tunisia)MiddleNone9 (Angola, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon, Sao Tome and Principe)East (8)Zimbabwe (2), Somalia (1), Uganda (1), Burundi (1), Tanzania (1), Zambia (1), Ethiopia (1)10 (Comoros, Djibouti, Eritrea, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, South Sudan)West (2)Nigeria (2)14 (Benin, Burkina Faso, Cabo Verde, Cote dIvoire, Gambia, Ghana, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Senegal, Sierra Leone, Togo)South (10)South Africa (10)4 (Botswana, Lesotho, Namibia, Swaziland)Asia (35)East (7)China (7)2 (North Korea, Mongolia)South (11)Pakistan (2), India (3), Nepal (3), Afghanistan (1), Iran (2)4 (Bangladesh, Bhutan, Maldives, Sri Lanka)South East (7)Vietnam (3), Malaysia (2), Indonesia (1), Thailand (1)4 (Cambodia, Laos, Philippines, Timor-Leste)West (9)Kuwait (1), Lebanon (3), Turkey (4), Iraq (1)7 (Armenia, Azerbaijan, Georgia, Jordan, Palestine, Syria, Yemen)Central (1)Tajikistan (1)4 (Kazakhstan, Kyrgyzstan, Turkmenistan, Uzbekistan)America (5)South (4)Brazil (2), Peru (2)6 (Bolivia, Colombia, Ecuador, Guyana, Paraguay, Suriname)Central (1)Mexico (1)7 (Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama)CaribbeanNone6 (Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica)Europe (1)Southern (1)Bosnia and Herzegovina (1)4 (Albania, Macedonia, Montenegro, Serbia)EasternNone5 (Belarus, Bulgaria, Moldova, Romania, Ukraine)OceaniaNone2 (Melanesia, Micronesia)Total (61^a^)^a^The country total is 61 instead of 58 as one study \[[@CR36]\] involved four countries (Mexico, China, Brazil and Pakistan)

The most commonly used tools to screen for generalized anxiety disorder were the Kessler-10 (K-10) and the Generalized Anxiety Disorder-7 item scale (GAD-7), totaling seven and six validations respectively. The Hopkins Symptom Checklist-25 item scale (HSCL-25), Hospital Anxiety and Depression Scale (HADS) and Hospital Anxiety and Depression Scale anxiety subscale (HADS-A) were validated almost equally while the majority of tools only had one validation (see Table [5](#Tab5){ref-type="table"}). PTSD had far fewer validations (19) with a wide range of tools receiving between one and three validations, similar to the screening tools validated for both anxiety and depression. Table 5Screening Tool by Disorder and Number of ValidationsDisorderScreening ToolNumber of ValidationsAnxiety disordersHADS-A3HADS3DASS-A1Zung SAS2STAI1EPDS2HAM-A1K107K63PHQ-41GAD-76HDRS1HSCL-254MINI-SPIN1PHC1GHQ-122SCARED/SCARED-C/−P1/1/1PASS1RCADS-GAD scale1BAI2Total46PTSDHTQ/−R1HTQ3K102PDS3PCL-C/−52/2CPSS2TSSC1UCLA PTSD Index1PTSD Screening Tool2Total19Anxiety and DepressionHSCL-252Independently developed (Zambia)1YSR1HADS1AKUADS1SRQ-201AYMH1HEI1K10/K61/1PHQ-41Total12*Abbreviations*: *HADS* Hospital Anxiety and Depression Scale, *HADS-A* Hospital Anxiety and Depression Scale Anxiety subscale, *DASS* Depression Anxiety Stress Scales, *Zung SAS* Zung Self-Rating Anxiety Scale, *STAI* State Trait Anxiety Inventory, *EPDS* Edinburgh Postnatal Depression Scale, *HAM-A* Hamilton Anxiety Rating Scale, *K10/K6* Kessler 10/6, *GAD* Generalized Anxiety Test, *HDRS* Hamilton Depression Rating Scale, *HSCL* Hopkins Symptom Checklist, *MINI-SPIN* Mini-Social Phobia Inventory, *PHC* Primary Health Care Screening Tool, *GHC* General Health Questionnaire, *SCARED* Screen for Child Anxiety Related Disorders, *PASS* Perinatal Anxiety Screening Scale, *RCADS* Revised Children's Anxiety and Depression Scales, *BAI* Beck Anxiety Inventory, *HTQ* Harvard Trauma Questionnaire, *PDS* Posttraumatic Diagnostic Scale, *PCL-C* PTSD Checklist-Clinician Version, *PHQ-4* Patient Health Questionnaire, *CPSS* Child PTSD Symptom Scale, *TSSC* Traumatic Stress Symptom Scale, *YSR* Youth Self-Report, *AKUADS* Aga Khan University Anxiety and Depression, *SRQ* Self-Reporting Questionnaire, *AYMH* Arab Youth Mental Health Scale, *HEI* Huaxi Emotional-Distress Index

Each included study is listed in Table [6](#Tab6){ref-type="table"} by region, screening tool and study quality with the respective sensitivity, specificity and cut-off for each disorder. Continentally, Asia had the most validations (35) and the majority of studies were considered unblinded (29). Due to incomplete reporting, we could meta-analyze results from only two studies, which involved the GAD-7; using a cut-off ≥10; sensitivity = 76%, specificity = 64%. Table 6Included studies listed by continent, sub-region, screening tool/disorder and qualityAuthor (year)Screening tool/disorderGold StandardSubregionCountryPopulationStudy QualityNo. ParticipantsPrevalence (%)DSM VersionAUCCut-Off Score (≥)Sensitivity (%)Specificity (%)**Africa** Ventevogel et al. (2014) \[[@CR37]\]CPSS/PTSDK-SADS-PLAfrica EastBurundiChildren aged 10--15good6523DSM 40.78267183 Chibanda et al. (2016) \[[@CR38]\]GAD-7/GADSCIDAfrica EastZimbabweAdults except pregnant womengood2643DSM 40.9108973 Kaaya et al. (2002) \[[@CR39]\]HSCL-25/Anxiety and depressionSCIDAfrica EastTanzaniaPregnant women with HIVgood903 (100 for SCID)3.3DSM 40.861.068980 Verhey et al. (2018) \[[@CR40]\]PCL-5/PTSDCAPS-5Africa EastZimbabweAdults except perinatal womenvery good20419.6DSM 50.783374.570.6 Odenwald et al. (2007) \[[@CR41]\]PDS/PTSDCIDIAfrica EastSomaliaPatients with trauma exposuregood135 (62 for CIDI)16.1DSM 40.874149079 Ertl et al. (2011) \[[@CR42]\]PDS/PTSDCAPSAfrica EastUgandaAdults and adolescents aged 12--25good6832.4DSM 40.79168270 Mbewe et al. (2013) \[[@CR43]\]self-made/Anxiety and depressionInterviewAfrica EastZambiaAdults with epilepsygood57553.7DSM 4x1756.568.1 Geibel et al. (2016) \[[@CR44]\]YSR/anxiety and depressionInterviewAfrica EastEthiopiaVulnerable teens assisted by two aid organizationsgood13464.6DSM 40.7296.57563.1 Saal (2019) \[[@CR45]\]Beck Anxiety Inventory/GADSCIDAfrica SouthSouth AfricaAdults undergoing HIV testingunblinded\*5003.4DSM 50.8621.58280 van Heyningen et al. (2018) \[[@CR46]\]EPDS/anxietyMINIAfrica SouthSouth AfricaAdult women in the antenatal periodunblinded\*37623DSM 40.6956759 Marsay et al. (2017) \[[@CR47]\]EPDS/anxietyNetSCIDAfrica SouthSouth AfricaAdult women pregnant for 22--28 weeksunblinded\*14514.5DSM 5x754.881.6 van Heyningen et al. (2018) \[[@CR46]\]GAD-2/anxietyMINIAfrica SouthSouth AfricaAdult women in the antenatal periodunblinded\*37623DSM 40.7326474 Seedat et al. (2007) \[[@CR48]\]HADS-A/anxietyMINIAfrica SouthSouth AfricaAdult schizophrenic patientsunblinded7022.9DSM 4x1137.572.2 Seedat et al. (2007) \[[@CR48]\]HAM-A/anxietyMINIAfrica SouthSouth AfricaAdult schizophrenic patientsunblinded7022.9DSM 4x2231.390.7 Myer et al. (2008) \[[@CR49]\]HTQ/PTSDMINIAfrica SouthSouth AfricaHIV-positive adultsgood4655DSM 40.74627470 Spies et al. (2009) \[[@CR50]\]K-10/AgoraphobiaMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42918.4DSM 70.69266567 van Heyningen et al. (2018) \[[@CR46]\]K10/anxietyMINIAfrica SouthSouth AfricaAdult women in the antenatal periodunblinded\*37623DSM 40.77117670 Andersen et al. (2011) \[[@CR51]\]K-10/Anxiety and DepressionCIDIAfrica SouthSouth AfricaAdultsunblinded4077xDSM 40.73167067 Spies et al. (2009) \[[@CR52]\]K10/GADMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42918.4DSM 40.78307280 Spies et al. (2009) \[[@CR50]\]K-10/GADMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42918.4x0.78307280 Spies et al. (2009) \[[@CR50]\]K-10/Panic disorderMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42915.3DSM 60.77287673 Spies et al. (2009) \[[@CR52]\]K-10/PTSDMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42921.5DSM 80.77297578 Spies et al. (2009) \[[@CR50]\]K-10/PTSDMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42921.5x0.77297578 Spies et al. (2009) \[[@CR50]\]K-10/Social anxietyMINIAfrica SouthSouth AfricaHIV-positive adultsunblinded\*42912.3DSM 50.9309280 van Heyningen et al. (2018) \[[@CR46]\]K6/anxietyMINIAfrica SouthSouth AfricaAdult women in the antenatal periodunblinded\*37623DSM 40.7786976 Andersen et al. (2011) \[[@CR51]\]K-6/Anxiety and DepressionCIDIAfrica SouthSouth AfricaAdultsunblinded4077xDSM 40.72107062 Martin et al. (2009) \[[@CR53]\]PDS/PTSDCIDIAfrica SouthSouth AfricaHIV-positive adultsunblinded85xDSM 40.741568.665 van der Westhuizen (2016) \[[@CR54]\]SRQ-20/Anxiety/DepressionMINIAfrica SouthSouth AfricaAdults with assault-related injury or accidentsunblinded\*200xICD 100.87583.376 Seedat et al. (2007) \[[@CR48]\]STAI/anxietyMINIAfrica SouthSouth AfricaAdult schizophrenic patientsunblinded7022.9DSM 4x407548.1 Makanjuola et al. (2014) \[[@CR55]\]GHQ-12/anxietyCIDIAfrica WestNigeriaAdult patients of general practicesunblinded1590xDSM 40.6135963.3 Abiodun et al. (1994) \[[@CR56]\]HADS/Anxiety and DepressionInterviewAfrica WestNigeriaAdult patients in non-psychiatric wards and communityunblinded\*1078Various†ICD 9x887.590.6 Makanjuola et al. (2014) \[[@CR55]\]K6/anxietyCIDIAfrica WestNigeriaAdult patients of general practicesunblinded1590xDSM 40.5846555**Asia** Hollander et al. (2007) \[[@CR21]\]HSCL-25/anxietyInterviewAsia CentralTajikistanAdult patients at outpatient clinicsacceptable75xDSM 4x1.68460 Hollander et al. (2007) \[[@CR21]\]HTQ-R/PTSDInterviewAsia CentralTajikistanAdult patients at outpatient clinicsacceptable75xDSM 4x1.739765 Tong et al. (2016) \[[@CR57]\]GAD-7/Generalized anxietyMINIAsia EastChinaAdults with epilepsy who were Chinese citizensunblinded21323.5DSM 40.97469491.4 Sheng et al. (2010) \[[@CR58]\]HADS-A/anxietyMINIAsia EastChinaAdult psychiatric outpatientsunblinded7025.5DSM 40.80568679 Yang et al. (2014) \[[@CR59]\]HADS-A/anxietyMINIAsia EastChinaAdult cardiac outpatientsunblinded\*10015DSM 40.81681.675.8 Wang et al. (2017) \[[@CR60]\]HEI/Anxiety and depressionMINIAsia EastChinaHospitalized patients aged 15+unblinded\*7637.11DSM 40.88118876.6 Liu et al. (2008) \[[@CR61]\]PTSD screening tool/PTSDDSM-IV PTSD criteriaAsia EastChinaSurvivors of a flood aged 16+unblinded27,2679.5DSM 40.858387.997.9 Liu et al. (2007) \[[@CR62]\]PTSD screening tool/PTSDDSM-IV PTSD criteriaAsia EastChinaChild survivors of a flood aged 7--15unblinded60734.6DSM 4x396.999 Ali et al. (1998) \[[@CR63]\]AKUADS/GAD and MDDInterviewAsia SouthPakistanResidents aged 16--60 in Karachi squatter settlementunblinded487xDSM 3x197481 Kohrt et al. (2003) \[[@CR64]\]BAI/anxietyDSM-IV criteriaAsia SouthNepalAdults with psychiatric illness and controlsacceptable363Various†DSM 4x149189 Thapa et al. (2005) \[[@CR65]\]PCL-C/PTSDCIDIAsia SouthNepalAdults residing in conflict areasunblinded29053.4DSM 40.81508080 Kohrt et al. (2011) \[[@CR66]\]CPSS/PTSDK-SADSAsia SouthNepalAdolescents aged 11--14good1626.4DSM 40.77206873 Chaturvedi et al. (1994) \[[@CR67]\]HADS/anxietyInterviewAsia SouthIndiaCancer patients of all agesunblinded\*70not specifiedDSM 3x78779 Ventevogel et al. (2007) \[[@CR68]\]HSCL/anxietyPASAsia SouthAfghanistanClinic patients aged 15+good11624.1x0.6127543 Ventevogel et al. (2007) \[[@CR68]\]HSCL/depression and anxietyPASAsia SouthAfghanistanClinic patients aged 15+good11624.1x0.6126967 Housen et al. (2018) \[[@CR69]\]HSCL-25/anxietyMINIAsia SouthIndiaAdult general medical outpatientsgood2903.5DSM 40.811.757381 Thapa et al. (2005) \[[@CR65]\]HSCL-25/anxietyCIDIAsia SouthNepalAdults residing in conflict areasunblinded29080.7DSM 40.761.757758 Ahmadi (2020) \[[@CR70]\]PHQ-4/anxietySCIDAsia SouthIranAdults with coronary heart diseaseunblinded\*279not specifiedDSM 50.9478094 Ahmadi (2020) \[[@CR70]\]PHQ-4/Anxiety and depressionSCIDAsia SouthIranAdults with coronary heart diseaseunblinded\*279not specifiedDSM 50.9478690 Russell et al. (2013) \[[@CR71]\]SCARED/anxietyK-SADS-PLAsia SouthIndiaAdolescents aged 11--19unblinded\*500xDSM 40.92184.687.36 Namazi et al. (2013) \[[@CR72]\]UCLA PTSD (PTSD)InterviewAsia SouthIranChildren aged 7--12 after earthquakeunblinded\*50564-Rx389650 Tran et al. (2013) \[[@CR73]\]DASS-A/anxietySCIDAsia South EastVietnamAdult perinatal womengood22110.9DSM 40.8061079.267 Sidik et al. (2012) \[[@CR74]\]GAD-7/anxietyCIDIAsia South EastMalaysiaAdult femalesgood8957.8DSM 4x87694 Yahya et al. (2015) \[[@CR75]\]HDRS/anxietyDSM-IVAsia South EastMalaysiaPatients with existing psychiatric disorder and controlsunblinded\*120xDSM 40.91789086.2 Silove et al. (2007) \[[@CR76]\]HTQ/PTSDSCIDAsia South EastThailandCambodian population in Thailandgood11820.3DSM 40.7126361 Tran et al. (2019) \[[@CR77]\]K-10/anxietyMINI-KIDAsia South EastIndonesiaAdolescents age 16--18unblinded\*196xDSM 40.821887.170.9 Tran et al. (2019) \[[@CR77]\]K-6/anxietyMINI-KIDAsia South EastIndonesiaAdolescents age 16--19unblinded\*196xDSM 40.81283.973.3 Tran et al. (2011) \[[@CR78]\]Zung SAS/anxietyInterviewAsia South EastVietnamAdult perinatal womengood36411.8DSM 40.793867.975.3 Tran et al. (2012) \[[@CR79]\]Zung SAS/anxietyInterviewAsia South EastVietnamMen who are partners of pregnant or perinatal womengood2315.2DSM 40.7753670.779 Mahfoud et al. (2011) \[[@CR80]\]AYMH/Anxiety and depressionInterviewAsia WestLebanonSocioeconomically disadvantaged children aged 10--14good15317.6DSM 40.71396379 Sawaya et al. (2016) \[[@CR81]\]GAD-7/anxietyInterviewAsia WestLebanonAdult psychiatric outpatientsacceptable176xDSM 40.57105753 Senturk et al. (2007) \[[@CR82]\]GHQ-12/anxietyCIDI-PHCVAsia WestTurkeyAdult leprosy patientsunblinded\*6512.3ICD 100.6957157 Malasi et al. (1991) \[[@CR83]\]HADS/anxietyInterviewAsia WestKuwaitAdult psychiatric outpatients and controlsacceptable135xDSM 3134547 Senturk et al. (2007) \[[@CR82]\]HADS/anxietyCIDI-PHCVAsia WestTurkeyAdult leprosy patientsunblinded\*65xICD 110.75116658 Yazici et al. (2018) \[[@CR84]\]PASS/anxietySCID-1Asia WestTurkeyAdult women in perinatal periodunblinded\*31219.2DSM 40.94169584 Ibrahim et al. (2018) \[[@CR85]\]PCL-5/PTSDDSM 5 interviewAsia WestIraqAdults living in a camp for displaced people in Iraqgood20637.75DSM 50.82238270 Gormez et al. (2017) \[[@CR86]\]RCADS-GAD scale/GADK-SADSAsia WestTurkeyChild psychiatry outpatients aged 8--17unblinded\*483not specifiedDSM 4x7.57071 Hariz et al. (2013) \[[@CR87]\]SCARED-C/anxietyInterviewAsia WestLebanonChild and adolescent psychiatric patientsgood8240.2DSM 40.63266656 Hariz et al. (2013) \[[@CR87]\]SCARED-P/anxietyInterviewAsia WestLebanonChild and adolescent psychiatric patientsgood82xDSM 40.7246755 Başoglu et al. (2001) \[[@CR88]\]TSSC/PTSDCAPSAsia WestTurkeySurvivors of 1999 August earthquake aged 16--70acceptable13049DSM 4x27673**Europe** Oruc et al. (2008) \[[@CR89]\]HTQ/(PTSD)SCIDEurope SouthernBosnia and HerzegovinaAdults enrolled in primary care clinicvery good18026DSM 40.982.0699.993.9**South America** Zhong et al. (2015) \[[@CR90]\]GAD-7/GADCIDISouth AmericaPeruPregnant women aged 18--49 who speak Spanishunblinded\*94633.3DSM 40.75773.367.3 de Lima Osório et al. (2007) \[[@CR91]\]MINI-SPIN/Social anxiety disorderSCIDSouth AmericaBrazilUniversity studentsfair232010.4DSM 40.8169446 Gelaye et al. (2017) \[[@CR92]\]PCL-C/PTSDCAPSSouth AmericaPeruPerinatal womenvery good32893DSM 40.75268663**Multiple Countries** Goldberg et al. (2017) \[[@CR36]\]PHC/current anxietyCIS-RSouth America, Asia South, Asia East, Central AmericaBrazil, Pakistan, China, MexicoPrimary care patientsfair1488 (all countries)Brazil: 26.5; Pakistan: 13; China: 18.9; Mexico: 23ICD 110.7737568**Meta-analyzed GAD-7 Values** Chibanda et al. (2016) \[[@CR38]\] and Sawaya et al. (2016) \[[@CR81]\]GAD-7/anxietyNANANANANANANANANA≥107664**Quality**: ranges from highest to lowest (very good, good, fair, acceptable, unblinded, unblinded\* (unblinded \[unconfirmed so considered unblinded\]); **x**: value not specified; **various†:** multiple values specified, see Appendix file; Abbreviations: *HADS* Hospital Anxiety and Depression Scale, *HADS-A* Hospital Anxiety and Depression Scale Anxiety subscale, *DASS* Depression Anxiety Stress Scales, *Zung SAS* Zung Self-Rating Anxiety Scale, *STAI* State Trait Anxiety Inventory, *EPDS* Edinburgh Postnatal Depression Scale, *HAM-A* Hamilton Anxiety Rating Scale, *K10/K6* Kessler 10/6, *GAD* Generalized Anxiety Test, *HDRS* Hamilton Depression Rating Scale, *HSCL* Hopkins Symptom Checklist, *MINI-SPIN* Mini-Social Phobia Inventory, *PHC* Primary Health Care Screening Tool, *GHC* General Health Questionnaire, *SCARED* Screen for Child Anxiety Related Disorders, *PASS* Perinatal Anxiety Screening Scale, *RCADS* Revised Children's Anxiety and Depression Scales, *BAI* Beck Anxiety Inventory; *HTQ* Harvard Trauma Questionnaire, *PDS* Posttraumatic Diagnostic Scale, *PCL-C* PTSD Checklist-Clinician Version, *PHQ-4* Patient Health Questionnaire, *CPSS* Child PTSD Symptom Scale, *TSSC* Traumatic Stress Symptom Scale, *YSR* Youth Self-Report, *AKUADS* Aga Khan University Anxiety and Depression, *SRQ* Self-Reporting Questionnaire, *AYMH* Arab Youth Mental Health Scale, *HEI* Huaxi Emotional-Distress Index

Discussion {#Sec13}
==========

This review aimed to examine the screening tools that have been validated to detect anxiety and PTSD in LMICs. The most commonly validated tools were the K-10 and GAD-7 for anxiety and the HTQ and the Posttraumatic Diagnostic Scale (PDS) for PTSD. It is difficult to recommend one screening tool for anxiety and PTSD respectively, as various tools and cut-off values were tested, and sensitivities and specificities varied based on region, country and screening tool. Indeed, only two studies tested the same tool using the same cut-off value and reported sufficient information to allow us to quantitatively synthesize the results. Locally validated screening tools for anxiety and PTSD need further evaluation in well-designed studies to assess whether they can improve the detection and management of these common disorders.

A total of 46 validated screening tools were found for anxiety disorders. The most common tool used to screen for anxiety disorders was the Kessler-10 followed by the GAD-7, which had wide ranges of sensitivities (57--94%) and specificities (53--94%) varying by region and sample size. While previously the HADS-A was recommended \[[@CR23]\], our updated review found that it was not as widely validated as the GAD-7 and Kessler-10, although it had consistent specificities (72--79%) with a range of sensitivities (38--86%). The Kessler may have an added time-efficiency component, as it is possible to screen for multiple common mental disorders, whereas screening tools such as the HADS-A target anxiety specifically. The GAD-7 reported some of the highest sensitivities for detection of generalized anxiety disorder. Other anxiety disorders, including agoraphobia, panic disorder and social anxiety disorder were less commonly validated. Our results are consistent with a previous systematic review \[[@CR23]\] and indicate using the GAD-7, K-10 or HAD-A yield good sensitivities and specificities while taking population-specific characteristics into account. Future research is needed to validate screening tools for these anxiety disorders in more regions.

The number of validations for PTSD increased from 10 to 19 since 2013 \[[@CR23]\]. The HTQ and PDS were the most commonly validated tools for PTSD, and sensitivities were generally high. Our findings add that in addition to the previously recommended HTQ, the PDS should be considered in screening for PTSD \[[@CR23]\]. Unfortunately, many tools were validated only once, preventing our combining them for analytic purposes. Only four PTSD validations describe children and adolescents, despite recent events that have displaced thousands of youth \[[@CR93]\]. The prevalence of PTSD remains high in LMICs and is expected to rise given increasing civil unrest and war \[[@CR19], [@CR94]\]. The year 2018 saw the highest recorded number of displaced persons globally leading the authors to emphasize more attention into detection and treatment of PTSD \[[@CR95]\].

Anxiety and depression had the fewest validations across our search \[[@CR11]\] though were not the target of our validation given the existing literature on depression alone \[[@CR23]\]. All tools with the exception of the HSCL-25 had only one validation. The only independently developed screening tool of all the studies was for anxiety and depression, developed in Zambia. These disorders commonly occur together, and further research is needed to determine which tools are best suited to a region's mental health screening needs.

We searched four databases with a robust library of psychiatric publications available. We also placed minimal exclusion criteria on our searches so as to maximize the number of studies returned, and we additionally reviewed relevant systematic reviews for additional relevant papers. At every stage of the process from title/abstract screen to data abstraction, two reviewers assessed each article and numerical data point to reduce human error. Our search strategy and protocol were published in PROSPERO and were not altered from the time of submission, with the exception that we did not calculate diagnostic odds ratios (DORs), as they provide no guidance to clinicians on what screening tool and cut-off threshold would be most appropriate to use in clinical practice. Rather, we reported sensitivity and specificity of each screening tool and cutoff separately, to better describe the accuracies of individual tools and cut-offs.

Our extraction was limited by the individual papers' specific data reporting. Varying prevalence of an individual study may affect the cut-off score, sensitivity and specificity of screening tools, and some studies did not publish prevalence. Providers should reference the prevalence of each specific disorder to ascertain whether the cut-off is applicable to their respective population. The majority of studies did not provide sensitivities and specificities for multiple cut-off values. Reporting multiple cut-off values and their respective sensitivity and specificity estimates would allow providers to decide which cut-off they would choose to optimize screening for their setting. A lower cut-off with a higher sensitivity may be desired if cases are not to be missed and false negatives reduced. A higher cut-off with a higher specificity may be desired if false positives are to be minimized. Furthermore, reporting multiple cut-off values and their respective sensitivity and specificity estimates would also allow researchers to better synthesize accuracy results across multiple studies in meta-analysis. In the present study, only two validations with identical cut-off scores for the GAD-7 could be combined via meta-analysis as no other validations of the same disorder with identical cut-off values provided sufficient information to conduct a meta-analysis (i.e., 2 × 2 table numbers). Studies used various versions of the DSM and ICD. While the symptomatology for psychiatric diagnoses have not changed significantly, providers should reference which version was used when conducting the validation of the screening tool (see Table [6](#Tab6){ref-type="table"}).

Our review was also limited by the available publications on mental health screenings in LMICs. The entire region of Middle and North Africa, constituting over 300 million people, was not represented by a single validation while other regions such as South-East Asia were fairly well-represented. Cultural and linguistic factors may influence screening tool validation yet further discussion may be best served for individual validation papers. Most studies were rated in the lowest quality category of the modified Greenhalgh scale as they were unblinded, or downgraded to unblinded due to incomplete reporting. This is a severe limitation in the design of studies that may impact validation results; future studies should ensure adequate blinding in addition to the remainder of the quality checklist.

Our study did not look at CMDs or depression specifically, although we did consider anxiety and depression when screened for together. We chose to focus on anxiety and PTSD as they are less well-represented in the realm of LMIC validated screening tools. Additionally, anxiety and PTSD are becoming more important with the current displacement of millions of people due to civil unrest, socioeconomic upheaval and war.

The number of validated screening tools for mental health disorders as a whole has increased since 2013 \[[@CR23]\]. However, no large increase in the number of validations for specific disorders was seen, and most screening tools from our search were validated only once. We advise researchers and providers to refer to Table [6](#Tab6){ref-type="table"} for a summary of validations for locations and disorders of interest and to use this table to identify their region of interest, find their disease focus of interest, and then identify what tools have been identified by the highest quality evidence.

Conclusions {#Sec14}
===========

Mental health disorders are highly prevalent yet are frequently stigmatized and disregarded as medical diseases. Validated screening tools for anxiety and PTSD in LMIC have made considerable progress, with validations for both disorders almost doubling since the prior systematic review completed in December 2013 \[[@CR23]\]. The increase in validated screening tools generally followed a regional pattern, with more emerging in countries already represented. For example, more tools have been validated in South Africa without an increase in validations in Botswana, Lesotho, Namibia or Swaziland. Middle and Northern Africa were also not well-represented by either anxiety or PTSD screening tools. The authors recognize that it may be near impossible to validate screening tools in areas of intense conflict and instability but acknowledge the need to evaluate screening tools in these areas.

The age distribution among screening tools was heavily biased towards the adult population. Children and adolescents accounted for only four of 19 validations for PTSD and six of 58 for anxiety and anxiety and depression. Given that age is skewed towards a younger population in LMICs \[[@CR35]\], it is imperative that more research focuses on identifying anxiety and PTSD disorders in a pediatric population, especially in areas of increased civil war and conflict.

Use of brief screening instruments can bring much needed attention and research opportunities to various at-risk populations in LMICs. Many screening tools for anxiety and PTSD have been validated in LMICs, but there remain regions and subgroups of individuals for which more research is needed. Locally validated screening tools for anxiety and PTSD should be further evaluated in clinical trials to determine whether their use can reduce the burden of disease.
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PTSD

:   Post-traumatic stress disorder

LMICs

:   Low to middle income countries

CMDs

:   Common mental disorders

MINI and MINI-KID

:   Mini International Neuropsychiatric Interview

SCID, SCID-1 and NetSCID

:   Structured Clinical Interview for DSM

CIDI and CIDI-PHCV

:   Composite International Diagnostic Interview

CIS-R

:   Clinical Interview Schedule-Revised

PAS

:   Psychiatric Assessment Schedule

K-SADS and K-SADS-PL

:   Kiddie Schedule for Affective Disorders and Schizophrenia

CAPS and CAPS-5

:   Clinician-Administered PTSD Scale

AUC

:   Area under the curve

ROC

:   Receiver operating characteristic curve

DORs

:   Diagnostic odds ratios

HADS

:   Hospital Anxiety and Depression Scale

DASS

:   Depression Anxiety Stress Scales

Zung SAS

:   Zung Self-Rating Anxiety Scale

STAI

:   State Trait Anxiety Inventory

EPDS

:   Edinburgh Postnatal Depression Scale

HAM-A

:   Hamilton Anxiety Rating Scale

K10/K6

:   Kessler 10/6

GAD

:   Generalized Anxiety Test

HDRS

:   Hamilton Depression Rating Scale

HSCL

:   Hopkins Symptom Checklist

MINI-SPIN

:   Mini-Social Phobia Inventory

PHC

:   Primary Health Care Screening Tool

GHC

:   General Health Questionnaire

SCARED

:   Screen for Child Anxiety Related Disorders

PASS

:   Perinatal Anxiety Screening Scale

RCADS

:   Revised Children's Anxiety and Depression Scales

BAI

:   Beck Anxiety Inventory

HTQ

:   Harvard Trauma Questionnaire

PDS

:   Posttraumatic Diagnostic Scale

PCL-C

:   PTSD Checklist-Clinician Version

CPSS

:   Child PTSD Symptom Scale

TSSC

:   Traumatic Stress Symptom Scale

CAPS

:   Clinician-Administered PTSD Scale

YSR

:   Youth Self-Report

AKUADS

:   Aga Khan University Anxiety and Depression

SRQ

:   Self-Reporting Questionnaire

AYMH

:   Arab Youth Mental Health Scale

HEI

:   Huaxi Emotional-Distress Index
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